Who We Are

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical, pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

Through the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), the Medical Countermeasures Systems (MCS) Joint Project Management Office is always looking for innovative, safe and effective medical solutions to counter CBRN threats. The usage of an OTA allows government to partner with the MCDC to leverage cutting edge R&D and develop prototypes from commercial sources. This gives MCS an agile and flexible way to develop medical countermeasures using new and innovative technology.

What We Do

The OTA Consortium is an enterprise partnership between the US Government (MCS) and the MCDC connected through a “contract-like” OTA.  This OTA operates outside the Federal Acquisition Regulations.

The MCDC provides the flexibility for better public and private collaboration by providing access to innovative concepts, ideas, and technologies from traditional and non-traditional technology providers.  Through the OTA with the MCDC, the JPEO-CBRND and MCS are looking to work with new industry partners to provide soldiers with safe and effective medical countermeasures.

The MCDC is currently recruiting a broad and diverse group of interested parties that includes representatives from large businesses, small businesses, traditional and non-traditional government contractors, academic research institutions, and not-for-profit organizations with collective expertise in the technology areas specifically related to the JPEO-CBRND/MCS mission.

Example Technical Areas of Interest:

  • Therapeutic MCM prototypes targeting viral, bacterial, and biological toxins and MCM enabling technologies
  • Single and multiple-drug autoinjector delivery devices
  • Vaccine-manufacturing platforms
  • Prototypes for the prophylaxis, treatment and diagnosis of CBRN threats, including Acute Radiation Syndrome and chemical nerve agents
  • Systems to increase the speed, accuracy, and confidence of agent identification and disease diagnosis
  • Advanced development and manufacturing capabilities